** Drugmaker Incyte Corp's INCY.O shares fall ~14% to $58.5 premarket
** Co's experimental drug, povorcitinib, meets the main goal of two separate late-stage studies testing it in patients with an inflammatory skin condition called hidradenitis suppurativa
** At least three analysts said that the data shows the drug is not as effective as its prior studies, which could make it less competitive against other treatments for the condition
** Novartis NOVN.S Cosentyx and UCB UCB.BR Bimzelx is already approved to treat this condition
** Truist securities analysts said that while the data will help get the drug approved, given the significant need for patients, its commercial potential may be impacted
** Hidradenitis suppurativa is an acne-like condition that causes painful bumps and lesions in and under the skin
** Up to last close, stock had risen 15.2% in the past 12 months
(Reporting by Siddhi Mahatole)
((siddhi.mahatole@thomsonreuters.com))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。